Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975891 · ClinicalTrials.gov registry record · Phase 4
Performance of Systane PRO Versus Refresh Optive Mega-3
A Phase 4 study of Dry Eye, sponsored by Scripps Poway Eyecare and Optometry.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06975891 is a Phase 4 study of Dry Eye that is actively recruiting participants, run by Scripps Poway Eyecare and Optometry. The registered enrollment target is 35 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06975891, a Phase 4 study of Dry Eye, is actively recruiting participants, sponsored by Scripps Poway Eyecare and Optometry.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.
Conditions Studied
Interventions
- DRUG Systane PRO
- DRUG Refresh Optive MEGA-3
Study Locations (1)
California
- Scripps Poway Eyecare & Optometry - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975891
The ClinicalTrials.gov registry entry for NCT06975891 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (63% lower). The listed sponsor is Scripps Poway Eyecare and Optometry, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Systane PRO is the first listed.
NCT06975891 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06975891 about?
NCT06975891 is a clinical study titled "Performance of Systane PRO Versus Refresh Optive Mega-3". Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.
What is the current status of trial NCT06975891?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-05-15. Estimated completion is 2026-06-01.
What conditions does trial NCT06975891 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT06975891?
The interventions under investigation include: Systane PRO (DRUG), Refresh Optive MEGA-3 (DRUG).
Who is sponsoring clinical trial NCT06975891?
This trial is sponsored by Scripps Poway Eyecare and Optometry, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06975891 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.